{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:01:39Z","timestamp":1784671299917,"version":"3.55.0"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020346","name":"Ningbo University Li Dak Sum Yip Yio Chin Kenneth Li Marine Biopharmaceutical Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020346","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004387","name":"Ningbo University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejmech.2026.118768","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:46:01Z","timestamp":1773272761000},"page":"118768","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["From structural evolution to an AI-driven future of 5-HT1F receptor agonists for migraine therapy"],"prefix":"10.1016","volume":"309","author":[{"given":"Lu","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiale","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahui","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dashuai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixiao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118768_bib1","series-title":"StatPearls","article-title":"Migraine medications","author":"Lew","year":"2025"},{"key":"10.1016\/j.ejmech.2026.118768_bib2","first-page":"1","article-title":"Cephalalgia","volume":"38","year":"2018","journal-title":"An Int. J. Headache"},{"key":"10.1016\/j.ejmech.2026.118768_bib3","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S1474-4422(25)00402-8","article-title":"Global, regional, and national burden of headache disorders, 1990-2023: a systematic analysis for the global burden of disease study 2023","volume":"24","year":"2025","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmech.2026.118768_bib4","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s10194-024-01798-z","article-title":"Global, regional, and national burden and trends of migraine among women of childbearing age from 1990 to 2021: insights from the global burden of disease study 2021","volume":"25","author":"Cen","year":"2024","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.ejmech.2026.118768_bib5","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s10194-025-02142-9","article-title":"The global prevalence of headache disorders of public-health importance: a meta-analysis of population-based individual participant data from 41,614 adults from 17 countries","volume":"26","author":"Hus\u00f8y","year":"2025","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.ejmech.2026.118768_bib6","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/head.14709","article-title":"Prevalence and burden of migraine in the United States: a systematic review","volume":"64","author":"Cohen","year":"2024","journal-title":"Headache"},{"key":"10.1016\/j.ejmech.2026.118768_bib7","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrneurol.2010.127","article-title":"CGRP and its receptors provide new insights into migraine pathophysiology","volume":"6","author":"Ho","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejmech.2026.118768_bib8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/biomedicines10010076","article-title":"Neurogenic inflammation: the participant in migraine and recent advancements in translational research","volume":"10","author":"Spekker","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2026.118768_bib9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40259-022-00530-0","article-title":"Calcitonin gene-related peptide (CGRP)-targeted monoclonal antibodies and antagonists in migraine: current evidence and rationale","volume":"36","author":"Cohen","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejmech.2026.118768_bib10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s10194-023-01644-8","article-title":"Mode and site of action of therapies targeting CGRP signaling","volume":"24","author":"Labastida-Ram\u00edrez","year":"2023","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.ejmech.2026.118768_bib11","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/bcp.12618","article-title":"CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment","volume":"80","author":"Edvinsson","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118768_bib12","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1093\/brain\/awae062","article-title":"Novel insight into atogepant mechanisms of action in migraine prevention","volume":"147","author":"Melo-Carrillo","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.ejmech.2026.118768_bib13","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1526-4610.2007.00993.x","article-title":"Comorbidity of migraine and psychiatric disorders--a national population-based study","volume":"48","author":"Jette","year":"2008","journal-title":"Headache"},{"key":"10.1016\/j.ejmech.2026.118768_bib14","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1111\/head.13914","article-title":"The effect of psychiatric comorbidities on headache\u2010related disability in migraine: results from the chronic migraine epidemiology and outcomes (CaMEO) study","volume":"60","author":"Lipton","year":"2020","journal-title":"Headache"},{"key":"10.1016\/j.ejmech.2026.118768_bib15","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0028-3908(99)00010-6","article-title":"A review of central 5-HT receptors and their function","volume":"38","author":"Barnes","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2026.118768_bib16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pharmthera.2015.01.009","article-title":"Structure and function of serotonin G protein-coupled receptors","volume":"150","author":"McCorvy","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.118768_bib17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0014-2999(99)00197-1","article-title":"Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy","volume":"375","author":"De Vries","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118768_bib18","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1046\/j.1468-2982.2002.00404.x","article-title":"Triptans (serotonin, 5-HT1B\/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials","volume":"22","author":"Ferrari","year":"2002","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ejmech.2026.118768_bib19","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000116756","article-title":"The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan","volume":"31","author":"Fowler","year":"2008","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.ejmech.2026.118768_bib20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1129-2377-15-48","article-title":"Treatment adherence among new triptan users: a 2-year cohort study in Taiwan","volume":"15","author":"Chen","year":"2014","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.ejmech.2026.118768_bib21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/sj.bjp.0703763","article-title":"Sumatriptan elicits both constriction and dilation in human and bovine brain intracortical arterioles","volume":"132","author":"Elhusseiny","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118768_bib22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0008-6363(98)00162-X","article-title":"Identification of mRNA for 5-HT1 and 5-HT2 receptor subtypes in human coronary arteries","volume":"41","author":"Ishida","year":"1999","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejmech.2026.118768_bib23","doi-asserted-by":"crossref","unstructured":"R. Acharya, S. Sapkota, L. Ruck, M. Abolbashari, Sumatriptan-induced coronary artery vasospasm leading to acute ST elevation myocardial infarction, Cureus 17 (n.d.) e80920. https:\/\/doi.org\/10.7759\/cureus.80920.","DOI":"10.7759\/cureus.80920"},{"key":"10.1016\/j.ejmech.2026.118768_bib24","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.bjp.0703081","article-title":"No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery","volume":"129","author":"Bouchelet","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118768_bib25","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1046\/j.1468-2982.2001.00208.x","article-title":"Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine","volume":"21","author":"Gomez-Mancilla","year":"2001","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ejmech.2026.118768_bib26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3389\/fneur.2016.00173","article-title":"Distribution of 5-HT1F receptors in monkey vestibular and trigeminal ganglion cells","volume":"7","author":"Usman","year":"2016","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejmech.2026.118768_bib27","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0028-3908(97)00020-8","article-title":"Cloning and characterization of the Guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog","volume":"36","author":"Adham","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2026.118768_bib28","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bph.15699","article-title":"The selective 5-HT1F receptor agonist lasmiditan inhibits trigeminal nociceptive processing: implications for migraine and cluster headache","volume":"179","author":"Vila-Pueyo","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118768_bib29","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s10194-024-01889-x","article-title":"Hallmarks of primary headache: part 1 - migraine","volume":"25","author":"Raggi","year":"2024","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.ejmech.2026.118768_bib30","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s40265-019-01225-7","article-title":"Lasmiditan: first approval","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118768_bib31","article-title":"Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: a systematic review and network meta-analysis of the literature","volume":"43","author":"S","year":"2023","journal-title":"Cephalalgia : An Int. J. Headache"},{"key":"10.1016\/j.ejmech.2026.118768_bib32","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/14740338.2024.2371382","article-title":"Safety profile of lasmiditan: a retrospective post-marketing pharmacovigilance study based on the real-world data of FAERS database","volume":"24","author":"Wan","year":"2025","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.ejmech.2026.118768_bib33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s10194-024-01745-y","article-title":"Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial","volume":"25","author":"Komori","year":"2024","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.ejmech.2026.118768_bib34","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s13311-023-01404-1","article-title":"The neuropsychiatric safety profile of lasmiditan: a comparative disproportionality analysis with triptans","volume":"20","author":"Merino","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejmech.2026.118768_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104282","article-title":"3D molecular generation models expand chemical space exploration in drug design","volume":"30","author":"Xiang","year":"2025","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.118768_bib36","series-title":"3D Equivariant Diffusion for Target-Aware Molecule Generation and Affinity Prediction","author":"Guan","year":"2023"},{"key":"10.1016\/j.ejmech.2026.118768_bib37","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s43588-024-00737-x","article-title":"Structure-based drug design with equivariant diffusion models","volume":"4","author":"Schneuing","year":"2024","journal-title":"Nat. Comput. Sci."},{"key":"10.1016\/j.ejmech.2026.118768_bib38","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1038\/s41467-024-46569-1","article-title":"A dual diffusion model enables 3D molecule generation and lead optimization based on target pockets","volume":"15","author":"Huang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118768_bib39","doi-asserted-by":"crossref","first-page":"7928","DOI":"10.1038\/s41467-025-63245-0","article-title":"Target-aware 3D molecular generation based on guided equivariant diffusion","volume":"16","author":"Hu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118768_bib40","article-title":"ProtoBind-Diff: a structure-free diffusion language model for protein sequence-conditioned ligand design","volume":"17","author":"Mistryukova","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.ejmech.2026.118768_bib41","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s42256-024-00808-8","article-title":"PocketFlow is a data-and-knowledge-driven structure-based molecular generative model","volume":"6","author":"Jiang","year":"2024","journal-title":"Nat. Mach. Intell."},{"key":"10.1016\/j.ejmech.2026.118768_bib42","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1038\/s41467-024-47011-2","article-title":"3D molecular generative framework for interaction-guided drug design","volume":"15","author":"Zhung","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118768_bib43","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/s41587-019-0224-x","article-title":"Deep learning enables rapid identification of potent DDR1 kinase inhibitors","volume":"37","author":"Zhavoronkov","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2026.118768_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2023.106072","article-title":"The putative role of neuroinflammation in the complex pathophysiology of migraine: from bench to bedside","volume":"180","author":"Biscetti","year":"2023","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejmech.2026.118768_bib45","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1152\/physrev.00034.2015","article-title":"Pathophysiology of migraine: a disorder of sensory processing","volume":"97","author":"Goadsby","year":"2017","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2026.118768_bib46","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1007\/s00415-023-11706-1","article-title":"Migraine: from pathophysiology to treatment","volume":"270","author":"Puledda","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.ejmech.2026.118768_bib47","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ncl.2019.07.008","article-title":"An update: pathophysiology of migraine","volume":"37","author":"Goadsby","year":"2019","journal-title":"Neurol. Clin."},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2026.118768_bib48","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/head.13300","article-title":"A phase-by-phase review of migraine pathophysiology","volume":"58","author":"Dodick","year":"2018","journal-title":"Headache"},{"key":"10.1016\/j.ejmech.2026.118768_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2024.1355281","article-title":"Advances in understanding migraine pathophysiology: a bench to bedside review of research insights and therapeutics","volume":"17","author":"Frimpong-Manson","year":"2024","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ejmech.2026.118768_bib50","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0028-3908(94)90067-1","article-title":"Localization of 5-HT1B, 5-HT1D alpha, 5-HT1E and 5-HT1F receptor messenger RNA in rodent and primate brain","volume":"33","author":"Bruinvels","year":"1994","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2026.118768_bib51","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s00210-005-1036-8","article-title":"[3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, Guinea pig, monkey and human brain","volume":"371","author":"Lucaites","year":"2005","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.ejmech.2026.118768_bib52","unstructured":"National Center for Biotechnology Information (NCBI), HTR1F gene, NCBI Gene (n.d.). https:\/\/www.ncbi.nlm.nih.gov\/gene\/3355 (accessed December 24, 2025)."},{"key":"10.1016\/j.ejmech.2026.118768_bib53","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1073\/pnas.90.2.408","article-title":"Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase","volume":"90","author":"Adham","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2026.118768_bib54","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1113\/jphysiol.2001.013175","article-title":"Distinct sensitizing effects of the cAMP-PKA second messenger cascade on rat dural mechanonociceptors","volume":"538","author":"Levy","year":"2002","journal-title":"J. Physiol."},{"key":"10.1016\/j.ejmech.2026.118768_bib55","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1097\/j.pain.0000000000001005","article-title":"Protein kinase A regulates inflammatory pain sensitization by modulating HCN2 channel activity in nociceptive sensory neurons","volume":"158","author":"Herrmann","year":"2017","journal-title":"Pain"},{"key":"10.1016\/j.ejmech.2026.118768_bib56","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1152\/physrev.00037.2003","article-title":"Vascular actions of calcitonin gene-related peptide and Adrenomedullin","volume":"84","author":"Brain","year":"2004","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2026.118768_bib57","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/head.13529","article-title":"CGRP and the trigeminal system in migraine","volume":"59","author":"Iyengar","year":"2019","journal-title":"Headache"},{"key":"10.1016\/j.ejmech.2026.118768_bib58","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/j.pain.0000000000001801","article-title":"Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system","volume":"161","author":"Labastida-Ram\u00edrez","year":"2020","journal-title":"Pain"},{"key":"10.1016\/j.ejmech.2026.118768_bib59","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.neulet.2016.10.054","article-title":"Abnormal mitochondrial dynamics and impaired mitochondrial biogenesis in trigeminal ganglion neurons in a rat model of migraine","volume":"636","author":"Dong","year":"2017","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejmech.2026.118768_bib60","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/head.13214","article-title":"The migraine attack as a homeostatic, neuroprotective response to brain oxidative stress: preliminary evidence for a theory","volume":"58","author":"Borkum","year":"2018","journal-title":"Headache"},{"key":"10.1016\/j.ejmech.2026.118768_bib61","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41582-019-0255-4","article-title":"The metabolic face of migraine - from pathophysiology to treatment","volume":"15","author":"Gross","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejmech.2026.118768_bib62","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3390\/life11050415","article-title":"The role of metabolism in migraine pathophysiology and susceptibility","volume":"11","author":"Grech","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.ejmech.2026.118768_bib63","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1124\/jpet.119.262410","article-title":"5-hydroxytryptamine 1F receptor agonist induces mitochondrial biogenesis and promotes recovery from spinal cord injury","volume":"372","author":"Simmons","year":"2020","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2026.118768_bib64","article-title":"5-HT1F receptor-mediated mitochondrial biogenesis for the treatment of Parkinson's disease","volume":"175","author":"Ne","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118768_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1344075","article-title":"Mitophagy regulates mitochondrial number following pharmacological induction of mitochondrial biogenesis in renal proximal tubule cells","volume":"15","author":"Hurtado","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118768_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113644","article-title":"The 5-hydroxytryptamine receptor 1F stimulates mitochondrial biogenesis and angiogenesis in endothelial cells","volume":"169","author":"Dupre","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118768_bib67","doi-asserted-by":"crossref","first-page":"F260","DOI":"10.1152\/ajprenal.00324.2017","article-title":"Identification of dual mechanisms mediating 5-hydroxytryptamine receptor 1F-induced mitochondrial biogenesis","volume":"314","author":"Gibbs","year":"2018","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ejmech.2026.118768_bib68","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0024-3205(97)00885-0","article-title":"Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine","volume":"61","author":"Phebus","year":"1997","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2026.118768_bib69","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0022-3565(24)34990-0","article-title":"5-Hydroxytryptamine(1F) receptors do not participate in vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin(1F) receptor agonist in rabbit saphenous vein","volume":"290","author":"Cohen","year":"1999","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2026.118768_bib70","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0014-2999(99)00067-9","article-title":"Both 5-HT1B and 5-HT1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis","volume":"369","author":"Mitsikostas","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118768_bib71","article-title":"5-Hydroxytryptamine(1B\/1D) and 5-hydroxytryptamine1F receptors inhibit capsaicin-induced c-fos immunoreactivity within mouse trigeminal nucleus caudalis","volume":"22","author":"Dd","year":"2002","journal-title":"Cephalalgia : An Int. J. Headache"},{"key":"10.1016\/j.ejmech.2026.118768_bib72","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/S0140-6736(01)06347-4","article-title":"Selective seratonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial","volume":"358","author":"Goldstein","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.118768_bib73","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00210-005-1035-9","article-title":"[3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties","volume":"371","author":"Wainscott","year":"2005","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.ejmech.2026.118768_bib74","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1046\/j.1468-2982.2003.00525.x","article-title":"5-HT1F receptor agonists in acute migraine treatment: a hypothesis","volume":"23","author":"Ramadan","year":"2003","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ejmech.2026.118768_bib75","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1021\/jm0155190","article-title":"N-[3-(2-Dimethylaminoethyl)-2-methyl-1H- indol-5-yl]-4-fluorobenzamide: a potent, selective, and orally active 5-HT(1F) receptor agonist potentially useful for migraine therapy","volume":"44","author":"Xu","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118768_bib76","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1021\/jm030020m","article-title":"Novel potent 5-HT(1F) receptor agonists: structure-activity studies of a series of substituted N-[3-(1-methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]amides","volume":"46","author":"Filla","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118768_bib77","article-title":"Substituted furo[3,2-b]pyridines: novel bioisosteres of 5-HT 1F receptor agonists","volume":"14","author":"Bm","year":"2004","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118768_bib78","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1016\/j.bmcl.2004.09.079","article-title":"Design, synthesis and evaluation of bicyclic benzamides as novel 5-HT1F receptor agonists","volume":"14","author":"Zhang","year":"2004","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118768_bib79","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1016\/j.bmcl.2015.07.042","article-title":"Discovery of selective N-[3-(1-methyl-piperidine-4-carbonyl)-phenyl]-benzamide-based 5-HT1 F receptor agonists: evolution from bicyclic to monocyclic cores","volume":"25","author":"Zhang","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118768_bib80","author":"Cohen"},{"key":"10.1016\/j.ejmech.2026.118768_bib81","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/0333102410370873","article-title":"Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan","volume":"30","author":"Nelson","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ejmech.2026.118768_bib82","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s10194-022-01394-z","article-title":"Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system; expression, release and interactions with 5-HT1 receptors","volume":"23","author":"Edvinsson","year":"2022","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.ejmech.2026.118768_bib83","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41422-021-00527-4","article-title":"Structural basis for recognition of anti-migraine drug lasmiditan by the serotonin receptor 5-HT1F\u2013G protein complex","volume":"31","author":"Huang","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2026.118768_bib84","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bph.15699","article-title":"The selective 5-HT1F receptor agonist lasmiditan inhibits trigeminal nociceptive processing: implications for migraine and cluster headache","volume":"179","author":"Vila-Pueyo","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118768_bib85","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3999\/jscpt.51.119","article-title":"Safety, tolerability, and pharmacokinetics of lasmiditan in healthy Japanese and caucasian subjects","volume":"51","author":"Komori","year":"2020","journal-title":"Rinsho Yakuri\/Japanese Journal of Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.ejmech.2026.118768_bib86","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/head.14122","article-title":"Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients","volume":"61","author":"Sakai","year":"2021","journal-title":"Headache"},{"key":"10.1016\/j.ejmech.2026.118768_bib87","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1080\/14740338.2022.2078302","article-title":"Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a phase 2 randomized placebo-controlled trial","volume":"21","author":"Hashimoto","year":"2022","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.ejmech.2026.118768_bib88","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/14740338.2022.2087630","article-title":"Safety profile of lasmiditan in patients with migraine in an Asian population","volume":"22","author":"Hirata","year":"2023","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.ejmech.2026.118768_bib89","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.2147\/JPR.S399567","article-title":"Lasmiditan in Japanese patients with common migraine comorbidities or concomitant medications: a post hoc safety and efficacy analysis from the MONONOFU study","volume":"16","author":"Kitamura","year":"2023","journal-title":"J. Pain Res."},{"key":"10.1016\/j.ejmech.2026.118768_bib90","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/0333102421989232","article-title":"Randomized, controlled trial of lasmiditan over four migraine attacks: findings from the CENTURION study","volume":"41","author":"Ashina","year":"2021","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ejmech.2026.118768_bib91","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s10194-021-01343-2","article-title":"Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine","volume":"22","author":"Tassorelli","year":"2021","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.ejmech.2026.118768_bib92","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1177\/0333102419864132","article-title":"Interim results of a prospective, randomized, open-label, phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)","volume":"39","author":"Brandes","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ejmech.2026.118768_bib93","doi-asserted-by":"crossref","DOI":"10.1177\/03331024231161745","article-title":"Long-term treatment with lasmiditan in patients with migraine: results from the open-label extension of the CENTURION randomized trial","volume":"43","author":"Ashina","year":"2023","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ejmech.2026.118768_bib94","series-title":"Summary Review for NDA 211280 (Lasmiditan)","year":"2019"},{"key":"10.1016\/j.ejmech.2026.118768_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113782","article-title":"Design, synthesis and biological evaluation of pyridinylmethylenepiperidine derivatives as potent 5-HT1F receptor agonists for migraine therapy","volume":"225","author":"Jin","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118768_bib96","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.omtn.2023.02.019","article-title":"Artificial intelligence for drug discovery: resources, methods, and applications","volume":"31","author":"Chen","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejmech.2026.118768_bib97","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1021\/acs.jcim.3c01517","article-title":"SerotoninAI: serotonergic system focused, artificial intelligence-based application for drug discovery","volume":"64","author":"\u0141api\u0144ska","year":"2024","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118768_bib98","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1021\/acs.jcim.0c00411","article-title":"Three-dimensional convolutional neural networks and a cross-docked data set for structure-based drug design","volume":"60","author":"Francoeur","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118768_bib99","author":"Masuda"},{"key":"10.1016\/j.ejmech.2026.118768_bib100","series-title":"Advances in Neural Information Processing Systems","first-page":"6840","article-title":"Denoising diffusion probabilistic models","author":"Ho","year":"2020"},{"key":"10.1016\/j.ejmech.2026.118768_bib101","doi-asserted-by":"crossref","first-page":"bbad435","DOI":"10.1093\/bib\/bbad435","article-title":"KGDiff: towards explainable target-aware molecule generation with knowledge guidance","volume":"25","author":"Qian","year":"2023","journal-title":"Briefings Bioinf."},{"key":"10.1016\/j.ejmech.2026.118768_bib102","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1039\/D4SC05894A","article-title":"DiffBP: generative diffusion of 3D molecules for target protein binding","volume":"16","author":"Lin","year":"2025","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2026.118768_bib103","series-title":"Advances in Neural Information Processing Systems","first-page":"6229","article-title":"A 3D generative model for structure-based drug design","author":"Luo","year":"2021"},{"key":"10.1016\/j.ejmech.2026.118768_bib104","series-title":"Proceedings of the 39th International Conference on Machine Learning","first-page":"17644","article-title":"Pocket2Mol: efficient molecular sampling based on 3D protein pockets","author":"Peng","year":"2022"},{"key":"10.1016\/j.ejmech.2026.118768_bib105","author":"Liu"},{"key":"10.1016\/j.ejmech.2026.118768_bib106","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/s42256-025-01095-7","article-title":"Electron-density-informed effective and reliable de novo molecular design and optimization with ED2Mol","volume":"7","author":"Li","year":"2025","journal-title":"Nat. Mach. Intell."},{"key":"10.1016\/j.ejmech.2026.118768_bib107","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/bioinformatics\/btv302","article-title":"GLASS: a comprehensive database for experimentally validated GPCR-ligand associations","volume":"31","author":"Chan","year":"2015","journal-title":"Bioinformatics"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T21:15:11Z","timestamp":1784668511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426002138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":107,"alternative-id":["S0223523426002138"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118768","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From structural evolution to an AI-driven future of 5-HT1F receptor agonists for migraine therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118768","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118768"}}